Semaglutide and Tirzepatide for Genetic Aging Delay in Adults With Obesity

What Was Tested

In this not phased trial, researchers set out to test Tirzepatide and Semaglutide.

This study is a prospective, randomized, open-label clinical trial enrolling 66 adults with simple obesity who have not used weight-loss medications for at least 3 months.

Participants will receive semaglutide, tirzepatide, or metformin for 24 weeks.

It had three arms (groups): Semaglutide Group (experimental), Tirzepatide Group (experimental) and Metformin Group (active comparator).

The registry classes the interventions as drug.

Who Took Part

66 planned participants were the target.

It was open to people of any sex aged from 18 years up to 75 years.

Healthy volunteers were not accepted; participants needed the condition being studied.

Examples of who could join: Adults aged 18 to 75 years. Diagnosed with simple obesity, defined as BMI ≥ 30 kg/m². Have not used any anti-obesity medications (including GLP-1 RAs, tirzepatide, metformin for weight loss, etc.) within the past 3 months. Able and willing to comply with study procedures and complete follow-up assessments. Provide written informed consent.

The full record lists 5 inclusion and 8 exclusion criteria; among the exclusions: use of anti-obesity medications or participation in another weight-loss program within the past 3 months; diagnosed type 1 or type 2 diabetes mellitus requiring hypoglycemic drug therapy; history of pancreatitis, severe gastrointestinal disease, or bariatric surgery.

How the Study Was Run

Design: randomized, parallel-group and open-label.

Random assignment meant chance, not the researchers, decided who got Tirzepatide and who got the comparison, which limits bias.

Groups ran in parallel: each of the participants stayed in one arm throughout.

Everyone knew when Tirzepatide was being given (open label), which is simpler to run but leaves more room for expectations to affect what is reported.

It started in 2025-06-02 with completion listed for 2027-04-02.

It ran at 1 site in China.

Its stated primary purpose is treatment.

What Was Measured

Primary outcome: Change in DNA methylation-based biological age measured by iWatchAge (time frame: Baseline and Week 24).

What This Means in Plain Language

Put simply, this is a not phased, randomized trial of Tirzepatide and Semaglutide in 66 people.

It is still recruiting; no results are posted to the registry yet, so nothing here describes outcomes.

More context: the Tirzepatide compound page and the Semaglutide compound page, all human trials.